Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price Today
Aura AI Summary
Key Stats
- $32.12BMarket Cap
- -Volume
- HealthSector
- $491.2252W High
- $205.4852W Low
- -Typical Hold Time
- $30.08BEnterprise Value
- -Div Yield
- -Trading Activity
Track Alnylam Pharmaceuticals, Inc. (ALNY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $205.48 and a high of $491.22, highlighting its annual price range. Buy and sell Alnylam Pharmaceuticals, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Most Recent News
Credit card balances overdue by 90 days have nearly doubled since 2022, while new delinquencies remain steady.
Since 2022, the amount of credit card debt that is 90 days overdue has almost doubled, indicating growing financial stress among borrowers. However, the rate of new delinquencies has not increased, suggesting that while existing overdue balances are ...
Sintana Energy boosts cash to $15.5M, advancing Atlantic Margin projects with key drilling planned.
Sintana Energy increased its cash reserves to $15.5 million by June 2026, following an $11.5 million fundraising in May and remains debt-free with additional credit facilities. The company is progressing its Atlantic Margin exploration with upcoming ...
Nvidia forecasts 70% revenue growth next year, driven by demand exceeding supply in AI chips.
Nvidia announced a forecast of about 70% revenue growth for its next financial year, marking the first time it has provided a full-year outlook. The company stated that the growth is limited by supply constraints rather than demand, with CEO Jensen H...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.